DE69428521T2 - Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid - Google Patents

Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid

Info

Publication number
DE69428521T2
DE69428521T2 DE69428521T DE69428521T DE69428521T2 DE 69428521 T2 DE69428521 T2 DE 69428521T2 DE 69428521 T DE69428521 T DE 69428521T DE 69428521 T DE69428521 T DE 69428521T DE 69428521 T2 DE69428521 T2 DE 69428521T2
Authority
DE
Germany
Prior art keywords
bpi
surfactant
compositions containing
bactericidal
medicinal compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69428521T
Other languages
English (en)
Other versions
DE69428521D1 (de
Inventor
Courtney Mcgregor
James Stubstad
Paul Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Publication of DE69428521D1 publication Critical patent/DE69428521D1/de
Application granted granted Critical
Publication of DE69428521T2 publication Critical patent/DE69428521T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DE69428521T 1993-02-02 1994-02-02 Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid Expired - Fee Related DE69428521T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1236093A 1993-02-02 1993-02-02
PCT/US1994/001239 WO1994017819A1 (en) 1993-02-02 1994-02-02 Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant

Publications (2)

Publication Number Publication Date
DE69428521D1 DE69428521D1 (de) 2001-11-08
DE69428521T2 true DE69428521T2 (de) 2002-05-23

Family

ID=21754603

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428521T Expired - Fee Related DE69428521T2 (de) 1993-02-02 1994-02-02 Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid

Country Status (13)

Country Link
US (5) US5488034A (de)
EP (1) EP0682524B1 (de)
JP (2) JP3946246B2 (de)
CN (1) CN1163264C (de)
AT (1) ATE206308T1 (de)
AU (1) AU695125B2 (de)
CA (1) CA2155005C (de)
DE (1) DE69428521T2 (de)
DK (1) DK0682524T3 (de)
ES (1) ES2164098T3 (de)
HK (1) HK1014156A1 (de)
PT (1) PT682524E (de)
WO (1) WO1994017819A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6277410B1 (en) 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5420019A (en) 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
AU7175694A (en) 1993-06-17 1995-01-17 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
EP0754049B1 (de) * 1994-01-14 2002-04-03 XOMA Technology Ltd. Antifungaleverfahren und mitteln
DK0754050T3 (da) * 1994-01-14 2002-10-21 Xoma Technology Ltd Anti-gram-positive bakterielle fremgangsmåder og materialer
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5830860A (en) * 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
JP2001520631A (ja) * 1995-07-20 2001-10-30 ゾーマ コーポレイション 抗真菌性ペプチド
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
JP2000501386A (ja) * 1995-11-14 2000-02-08 ゾーマ コーポレイション 角膜損傷に関連する病態を処置するための、殺菌性／透過性増強（ｂｐｉ）タンパク質
DE69703689T2 (de) * 1996-05-10 2001-05-10 Xoma Technology Ltd Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
AU736096B2 (en) * 1996-05-23 2001-07-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
JP2000511892A (ja) 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 可溶性ベーターシート形成性ペプチドの合成
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
WO1998013069A2 (en) 1996-09-09 1998-04-02 Supratek Pharma, Inc. Fluorinated copolymeric pharmaceutical adjuncts
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
AU744918B2 (en) * 1996-11-01 2002-03-07 Xoma Corporation Therapeutic uses of BPI protein products in cystic fibrosis patients
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
FR2764800B1 (fr) * 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US5990082A (en) 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1173195B1 (de) * 1999-04-21 2007-10-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Uteroglobin zur behandlung von iga vermittelten autoimmunerkrankungen
US6413537B1 (en) 2000-03-10 2002-07-02 Wisconsin Alumni Research Foundation Nystatin formulation having reduced toxicity
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CN1604788B (zh) * 2001-10-16 2013-04-17 里克斯金蒂克斯公司 高浓度蛋白制剂及其制备方法
WO2003070751A2 (en) 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
DK1567191T3 (da) * 2002-11-26 2011-01-03 Eurocine Vaccines Ab Ny amin-baseret adjuvans
EP1598074B1 (de) * 2003-02-28 2019-01-02 Chugai Seiyaku Kabushiki Kaisha Proteinhaltige stabilisierte vorrichtung
MXPA05010635A (es) * 2003-04-02 2005-12-12 Ares Trading Sa Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
US7838721B2 (en) * 2003-04-09 2010-11-23 Paragon Trade Brands, Llc Disposable articles using high column AUL superabsorbents
EP1638595B1 (de) * 2003-06-20 2013-03-20 Ares Trading S.A. Gefriergetrocknete fsh / lh formulierungen
US8377459B2 (en) * 2003-07-09 2013-02-19 The Procter & Gamble Company Composition for wet wipes that enhances the efficacy of cleansing while being gentle to the skin
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
US7150995B2 (en) * 2004-01-16 2006-12-19 Metrika, Inc. Methods and systems for point of care bodily fluid analysis
EP1778279B1 (de) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmazeutische zusammensetzung mit botulinum neurotoxin a2
PT2813239T (pt) * 2004-08-04 2017-06-09 Ipsen Biopharm Ltd Composição farmacêutica contendo a neurotoxina botulínica a2
US20060173428A1 (en) * 2005-02-02 2006-08-03 Acors Deanna M Absorbent article with logically correlated image and textual graphics
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2009021173A1 (en) * 2007-08-08 2009-02-12 Advanced Liquid Logic, Inc. Use of additives for enhancing droplet operations
WO2009034958A1 (ja) * 2007-09-12 2009-03-19 Jsr Corporation タンパク安定化剤およびその製造方法、タンパク安定化剤の使用方法、ならびにタンパク安定化方法
EP2310412B1 (de) 2008-06-20 2018-02-21 Novartis AG Immunglobuline mit verminderter aggregation
KR20180056805A (ko) 2009-06-04 2018-05-29 노파르티스 아게 ＩｇＧ 콘쥬게이션을 위한 자리의 확인 방법
RS61683B1 (sr) 2010-06-25 2021-05-31 Shire Human Genetic Therapies Isporuka terapijskih agenasa u centralni nervni sistem
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
GB201116271D0 (en) * 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
IL285716B (en) 2014-05-07 2022-09-01 Applied Molecular Transp Llc Compacted molecules derived from colic toxin for oral delivery of biologically active cargo
PT3762009T (pt) 2018-03-08 2022-08-22 Applied Molecular Transport Inc Construções de administração derivadas de toxinas para administração oral
EP4316586A2 (de) 2018-03-08 2024-02-07 Applied Molecular Transport Inc. Toxinabgeleitete freisetzungskonstrukte zur oralen freisetzung
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
CN115666522A (zh) * 2020-03-18 2023-01-31 Gi医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白制剂
BR112023019201A2 (pt) * 2021-03-24 2023-10-17 Japan Chem Res Composição farmacêutica aquosa ou composição farmacêutica liofilizada

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839314A (en) * 1971-06-29 1974-10-01 Baxter Laboratories Inc Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4933179A (en) * 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
DE3406497A1 (de) * 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US5234683A (en) * 1985-06-18 1993-08-10 Emory University Method of stimulating the immune system
US5039520A (en) * 1986-05-15 1991-08-13 Emory University Plasma extender
US5152979A (en) * 1986-05-15 1992-10-06 Emory University Method for treating vascular obstructions caused by abnormal cells
US5041288A (en) * 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5030448A (en) * 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US5071649A (en) * 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5182106A (en) * 1986-05-15 1993-01-26 Emory University Method for treating hypothermia
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
AU1396588A (en) * 1987-02-20 1988-09-14 Emory University Antiinfective compounds and method of use
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JPH02107163A (ja) * 1988-10-15 1990-04-19 Suntory Ltd 新規なゲル状食品の製造方法
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US4997664A (en) * 1989-09-05 1991-03-05 Bryan Foods, Inc. Method for packaging food products
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5234908A (en) * 1991-04-12 1993-08-10 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
EP0605653A4 (de) * 1991-09-26 1995-03-15 Incyte Pharma Inc Neue art eines liposaccharid bindendes protein (lbp).
WO1993023540A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
EP0682524B1 (de) * 1993-02-02 2001-10-04 XOMA Technology Ltd. Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products

Also Published As

Publication number Publication date
CA2155005C (en) 1999-04-06
CN1163264C (zh) 2004-08-25
CA2155005A1 (en) 1994-08-18
US6255284B1 (en) 2001-07-03
WO1994017819A1 (en) 1994-08-18
PT682524E (pt) 2002-03-28
EP0682524B1 (de) 2001-10-04
US6066620A (en) 2000-05-23
US5488034A (en) 1996-01-30
ATE206308T1 (de) 2001-10-15
HK1014156A1 (en) 1999-09-24
AU6133094A (en) 1994-08-29
AU695125B2 (en) 1998-08-06
US5955427A (en) 1999-09-21
DK0682524T3 (da) 2002-01-28
US5696090A (en) 1997-12-09
JPH10513433A (ja) 1998-12-22
DE69428521D1 (de) 2001-11-08
JP3946246B2 (ja) 2007-07-18
JP2005145986A (ja) 2005-06-09
CN1127992A (zh) 1996-07-31
ES2164098T3 (es) 2002-02-16
EP0682524A1 (de) 1995-11-22

Similar Documents

Publication Publication Date Title
DE69428521T2 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DK0458894T3 (da) Lipidexcipiens til nasal afgivelse og topisk påføring
DE69312947D1 (de) Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
NL300212I1 (nl) ASP-B28 insulinekristallen.
FI962154A0 (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
ATE187740T1 (de) Modifizierte proteine und peptide enthaltende pharmazeutische mittel
ATE177645T1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
IT1272252B (it) Formulazioni liquide di interferone beta
ES2087337T3 (es) Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
TR200102265T2 (tr) Anestezi düzenlemesi.
ATE215361T1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
DE60044468D1 (de) Herstellung von sekretierten polypeptiden
CO4230067A1 (es) Composicion cosmetica para el cuidado de la piel
TH31627A (th) องค์ประกอบแห้ง
DE69707690T2 (de) Neue peptide und nootroper wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee